@article{Kerr_S-2022_65649,
title = {First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales},
author = {Kerr, S. and Joy, M. and Torabi, F. and Bedston, S. and Akbari, A. and Agrawal, U. and Beggs, J. and Bradley, D. and Chuter, A. and Docherty, A. and Ford, D. and Hobbs, R. and Katikireddi, S. and Lowthian, E. and de Lusignan, S. and Lyons, R. and Marple, J. and McCowan, C. and McGagh, D. and McMenamin, J. and Moore, E. and Murray, J. and Owen, R. and Pan, J. and Ritchie, L. and Shah, S. and Shi, T. and Stock, S. and Tsang, R. and Vasileiou, E. and Woolhouse, M. and Simpson, C. and Robertson, C. and Sheikh, A.},
month = {feb},
year = {2022},
abstract = {BackgroundSeveral countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis (CVST). Large datasets are required to precisely estimate the association between Coronavirus Disease 2019 (COVID-19) vaccination and CVST due to the extreme rarity of this event. We aimed to accomplish this by combining national data from England, Scotland, and Wales.},
volume = {19},
issue = {2},
journal = {PLoS Medicine},
publisher = {},
url = {https://doi.org/10.1371/journal.pmed.1003927},
}
